HUM vs IKT · P/E 39, rev $129.66B vs $215.2M cap
Humana Inc (HUM) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported HUM revenue for 2025-12-31 was $129.66B. Net income was $1.19B. Revenue was up 10.1% from 2024-12-31 to 2025-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported IKT revenue for 2024-12-31 was $0. Net income was -$27.5M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. IKT currently screens at market cap $215.2M.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. IKT currently screens at market cap $215.2M.
Not investment advice. Open the HUM and IKT stock pages for the full models.
Not investment advice.